	Liklihood of				Actual			
Estimated savings for 16-17	Achieving Estimate	Gross savings £000's	Investment £000's	Net Savings £000's	Savings £000's	Full Year Effect	Unavoidable Spending Increases	Estimated gross Increase £000'
Primary Care:	Louinato	Order cavings 2000 c	mirodinioni 2000 0	not outlings 2000 0	20000	Ziioot		
							B	
General Prescribing Support input.	High	31		31			Price Increases	
Scriptswitch (all practices)	Medium	120	40	60	20.01		Ropinirole (shortage)	TBC
Prescribing Efficiency LES - Non Clinical Med Review	Medium	84	36	48				
Prescribing Efficiency LES -								
Oxycodone brand change	High	60	13	47	'			
Prescribing Efficiency LES -								
Combination inhaler review	High	18.7	20.6	-1.9				
Prescribing Efficiency LES - repeat								
prescribing system review	Low	42		1				
PST Technicians reviews	High	45						
Flu vaccine reduced cost	High	55.76		00110				
Patent Expiries	Medium	39.3	3 0	00.0				
Polypharmacy	Medium			0				
Primary Care Rebates	Medium	6.5	5 C	6.5		9.5		
Blood glucose meter and Insulin needle		_		_				
swap	High	56.5	S C	56.5				
Sub total		558.76	196	342.76	20.01	9.5		
Waste Programme	Low							
Sub total	LOW	0) 0)	0	0		
Secondary Care - aim £60k			, ,		0	0		
	1.							
Rituximab biosimilar	Low	100	0	100			Rifampicin capsules shortage	TBC
Etanercept biosimilar	Medium	240	50	190			Zoledronic acid 5mg contract shortage	TBC
IV fluids - new clinical guidance	High			O				
Infliximab biosimilar Introduction	High	33.41	0	33.41	13.22			
Patent Expiry	Medium	331.1		0				
High Cost Drugs to HBP	High			0				
pegfilgrastim to Lipegfilgrastim	1				11100			
(formulary change)	High	8.26		8.26	;			
Apixaban reduced price	High			0				
Bendamustine reduced price	High	30)	30				
Linezolid reduced price	Medium	7.5	5 0					
Rituximab ready made bags - reduced								
price	High	3.74	· c	3.74				
Golimumab outcome rebate	High		C					
HIV Drugs	High		C	0				
Off Contract Recovery	High		C	0				
Adrenaline pen brand change	High	40	0	40				
Oxycodone brand change	High			0				
Secukinemab FOC initiation	High			0	8.24			
Dexamethasone product change	High	7.33	3	7.33		11		
Sub total	3	470.24						
Total		1029	246	763	102.19	20.5		
Non Cash Efficiencies		Length of Stay	Patients Admitted					
The state of the s		_ongin or oray	. attorito Admittou					